Skip to main content
Premium Trial:

Request an Annual Quote

Fisher Scientific Products and Services Revenue Jumps 42 Percent in Third Quarter

NEW YORK, Nov. 4 (GenomeWeb News) - Fisher Scientific today said that third-quarter revenues increased 42 percent, which includes a 50-percent rise in revenue from scientific products and services.

Fisher Scientific's third-quarter revenues swelled to $1.2 billion from $890 million in the third quarter of 2003. Revenues from scientific products and services rose to $945 million from $632 million year over year.


Sales of scientific products and services in the recent quarter totaled $922.8 million, an increase of 46 percent compared to the third quarter of 2003.


Apogent and Oxoid, the company's molecular biology-supply unit, and Dharmacon, a recent acquisition, contributed revenue to Fisher's scientific products and services income. However, the Hampton, NH-based firm did not break out revenues by unit.


Net income dropped to $10.8 million, or $.10 per diluted share, from $27.7 million, or $.47 per share, year over year.


Fisher reported $296.4 million in cash and cash equivalents available on Sept. 30, part of the company's $7.9 billion of total assets.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.